Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Repligen Corporation (RGEN : NSDQ)
 
 • Company Description   
Repligen Corporation is a leading provider of advanced bioprocessing technologies and solutions used by large biopharmaceutical companies and contract manufacturing organizations for manufacturing biologic drugs, such as monoclonal antibodies (mAbs) and gene therapies. Repligen earns revenues from the sale of several products, which can be categorized mainly under three segments, namely Filtration, Chromatography and Protein products. The chromatography products include OPUS and OPUS PD chromatography columns, chromatography resins and ELISA test kits. Filtration products consist of XCell Alternating Tangential Flow (ATF) Systems and consumables, KrosFlo filtration products and SIUS filtration products. Protein products comprise the Protein A ligands and cell culture growth factors.

Number of Employees: 1,852

 
 • Price / Volume Information   
Yesterday's Closing Price: $149.96 Daily Weekly Monthly
20 Day Moving Average: 716,200 shares
Shares Outstanding: 54.43 (millions)
Market Capitalization: $8,162.19 (millions)
Beta: 0.98
52 Week High: $327.32
52 Week Low: $137.21
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -1.63% 7.78%
12 Week -17.00% -9.94%
Year To Date -43.38% -32.67%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
41 SEYON STREET BUILDING 1 SUITE 100
-
WALTHAM,MA 02453
USA
ph: 781-250-0111
fax: 781-250-0115
investors@repligen.com http://www.repligen.com
 
 • General Corporate Information   
Officers
Tony J. Hunt - Chief Executive Officer and President
Karen Dawes - Chairperson
Jon K. Snodgres - Chief Financial Officer
Nicolas M. Barthelemy - Director
Carrie Eglinton Manner - Director

Peer Information
Repligen Corporation (CORR.)
Repligen Corporation (RSPI)
Repligen Corporation (CGXP)
Repligen Corporation (BGEN)
Repligen Corporation (GTBP)
Repligen Corporation (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 759916109
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 07/26/22
Share - Related Items
Shares Outstanding: 54.43
Most Recent Split Date: (:1)
Beta: 0.98
Market Capitalization: $8,162.19 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $0.73 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $3.10 Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: 0.00
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 07/26/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 48.37
Trailing 12 Months: 45.44
PEG Ratio: -
Price Ratios
Price/Book: 4.62
Price/Cash Flow: 36.81
Price / Sales: 11.12
EPS Growth
vs. Year Ago Period: 35.29%
vs. Previous Quarter: 13.58%
Sales Growth
vs. Year Ago Period: 44.50%
vs. Previous Quarter: 10.66%
ROE
03/31/22 - 11.13
12/31/21 - 10.58
09/30/21 - 9.81
ROA
03/31/22 - 8.46
12/31/21 - 8.21
09/30/21 - 7.77
Current Ratio
03/31/22 - 2.23
12/31/21 - 2.48
09/30/21 - 2.61
Quick Ratio
03/31/22 - 1.72
12/31/21 - 1.99
09/30/21 - 2.16
Operating Margin
03/31/22 - 25.91
12/31/21 - 26.14
09/30/21 - 26.49
Net Margin
03/31/22 - 19.86
12/31/21 - 19.13
09/30/21 - 20.06
Pre-Tax Margin
03/31/22 - 24.43
12/31/21 - 22.90
09/30/21 - 22.52
Book Value
03/31/22 - 32.45
12/31/21 - 31.65
09/30/21 - 31.02
Inventory Turnover
03/31/22 - 1.75
12/31/21 - 1.91
09/30/21 - 1.98
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©